1-3 of 3
Sanjeev Luther
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Complete Remission with Devimistat (CPI-613) in Refractory Burkitt Lymphoma

Liana Nikolaenko, Timothy Pardee, Raphel Steiner, Jeremy S. Abramson, Steven M. Horwitz, Matthew J. Matasar, Colette Owens, Ildefonso Rodriguez-Rivera, David J. Straus, Sanjeev Luther, Ariela Noy
Journal: Blood
Blood (2021) 138 (Supplement 1): 4555.
https://doi.org/10.1182/blood-2021-153662
Published: 2021
Journal Articles

A Phase II Clinical Trial of Cpi-613 (devimistat) in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with Rearrangements of MYC and BCL2 and/or BCL6

Ariela Noy, MD, Timothy S. Pardee, MD PhD, Liana Nikolaenko, MD, Raphael Eric Steiner, MD, Jeremy S. Abramson, MD MMSc, Kieron Dunleavy, MD, Sanjeev Luther, MBA
Journal: Blood
Blood (2019) 134 (Supplement_1): 4087.
https://doi.org/10.1182/blood-2019-131563
Published: 2019
Journal Articles

Multicentre, Open Label, Randomized Phase III Study of Cpi-613 ® (devimistat) in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (≥ 60 years) with Relapsed / Refractory Acute Myeloid Leukemia (AML) - Armada 2000 (AML003) Trial

Timothy S. Pardee, MD PhD, Sanjeev Luther, MBA, Marc E. Buyse, ScD, Bayard L Powell, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2658.
https://doi.org/10.1182/blood-2019-129377
Published: 2019